Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer Cells

Background: Natalizumab is a humanized monoclonal antibody directed against very late activation antigen 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis. Blockade of VLA-4 with natalizumab may not only interfere with autoimmunological mechanisms but also with central nerv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European neurology 2010-05, Vol.63 (5), p.311-317
Hauptverfasser:	Putzki, Norman, Baranwal, Manoj Kumar, Tettenborn, Barbara, Limmroth, Volker, Kreuzfelder, Ernst
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized B-Lymphocytes - drug effects B-Lymphocytes - metabolism CD4 Antigens - metabolism CD8 Antigens - metabolism Cell Proliferation - drug effects Female Humans Immunologic Factors - pharmacology In Vitro Techniques Integrin alpha4beta1 - metabolism Interleukin-2 Receptor alpha Subunit - metabolism Killer Cells, Natural - drug effects Killer Cells, Natural - metabolism Leukocytes - drug effects Leukocytes - metabolism Longitudinal Studies Male Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Multiple Sclerosis, Relapsing-Remitting - metabolism Natalizumab Original Paper T-Lymphocytes, Regulatory - drug effects T-Lymphocytes, Regulatory - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!